Nov 17, 2025 • Motley Fool
SOMEWHAT-BULLISH
Centessa Stock Has Surged 77% Over the Past Year - But a Top Biotech Fund Is Still Buying
A science-first biotech fund is leaning deeper into one company just as its lead program delivers some compelling early neuro data.
Nov 12, 2025 • Motley Fool
NEUTRAL
Why Centessa Pharmaceuticals Stock Crushed the Market Today
Investors were optimistic about the company potentially reaping $250 million in gross proceeds from an equity offering.
Nov 12, 2025 • GlobeNewswire
NEUTRAL
Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares
BOSTON and LONDON, Nov. 11, 2025 ( GLOBE NEWSWIRE ) -- Centessa Pharmaceuticals plc ( Nasdaq: CNTA ) , a clinical-stage pharmaceutical company, today announced the pricing of an underwritten public offering of 11,627,907 American Depositary Shares ( "ADSs" ) , each representing one ordinary ...
Nov 07, 2025 • Benzinga
NEUTRAL
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences - Centessa Pharmaceuticals ( NASDAQ:CNTA )
BOSTON and LONDON, Nov. 07, 2025 ( GLOBE NEWSWIRE ) -- Centessa Pharmaceuticals plc ( NASDAQ:CNTA ) , a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the ...
Oct 28, 2025 • Benzinga
NEUTRAL
This Domino's Pizza Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Ameren ( NYSE:AEE ) , Centessa Pharmaceuticals ( NASDAQ:CNTA )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Aug 12, 2025 • GlobeNewswire
NEUTRAL
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025
Advancing a broad, potential best-in-class orexin receptor 2 ( OX2R ) agonist franchise, with key data readouts expected this year ...